Inhibitors of hemopoietic cell kinase (p-59-hck) and their use in the treatment of influenza infection

A method for the treatment of infection by influenza virus (A, B and C strains) comprising administering to a subject in need thereof a therapeutically effective amount of a compound capable of inhibiting hemopoietic cell kinase (p59-HCK) activity in the subject wherein the chemical inhibitor is a compound of formula (I)

• wherein R is C1-6 alkyl optionally substituted by a hydroxyl group;
• R2 is H or C1-6 alkyl optionally substituted by a hydroxyl group;
• R3 is H, C1-6 alkyl or C0-3 alkylC3-6 cycloalkyl;
• Ar is a naphthyl or a phenyl ring, each optionally substituted by one or more substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, amino, and C1-4 mono or C2-8 di-alkyl amino;
• L is a saturated or unsaturated branched or unbranched C1-8 alkylene chain, wherein one or more carbons are optionally replaced by —O—, and the chain is optionally substituted by one or more halogen atoms;
• X is 5 or 6 membered heteroaryl group containing at least one nitrogen atom and optionally including 1 or 2 further heteroatoms selected from the group consisting of O, S and N;
• and
• Q is selected from the group consisting of:
• a) a saturated or unsaturated, branched or unbranched C1-10 alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, S(O)p, wherein said chain is optionally substituted by one or more substituents independently selected from the group consisting of oxo, halogen, an aryl group, a heteroaryl group, a heterocyclyl group and a C3-8 cycloalkyl group, each aryl, heteroaryl, heterocyclyl or C3-8 cycloalkyl group having 0 to 3 substituents selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, amino, C1-4 mono or C2-8 di-alkyl amino, C1-4 mono or C2-8 di-acyl amino, S(O)qC1-6 alkyl, C0-6 alkylC(O)C1-6 alkyl and C0-6 alkylC(O)C1-6 heteroalkyl, wherein p is 0, 1 or 2, with the proviso that the atom linked directly to the carbonyl in —NR3C(O)— is not an oxygen or a sulfur atom;
• and
• b) a C0-8 alkyl-heterocycle, said heterocyclyl group comprising at least one heteroatom selected from the group consisting of O, N, and S, optionally substituted with one, two or three groups independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, amino, C1-4 mono and C2-8 di-alkyl amino, C1-4 mono or C2-8 di-acyl amino, S(O)qC1-6 alkyl, C0-6 alkylC(O)C1-6 alkyl, C0-6 alkylC(O)NC0-6 alkyl C0-6 alkyl and C0-6 alkylC(O)C0-6 heteroalkyl, wherein q is 0, 1 or 2;
• or a pharmaceutically acceptable salt or solvate thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.